US Stock MarketDetailed Quotes
IVBIY INNOVENT BIOLOGICS INC UNSPON ADS EACH REP 4 ORD SHS
- 19.150
- 0.0000.00%
15min DelayClose Nov 21 16:00 ET
7.80BMarket Cap-42841P/E (TTM)
0.000High0.000Low0Volume0.000Open19.150Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)407.10MShares22.00052wk High4.55P/B7.80BFloat Cap19.15052wk Low--Dividend TTM407.10MShs Float22.000Historical High--Div YieldTTM0.00%Amplitude19.150Historical Low--Avg Price1Lot Size
INNOVENT BIOLOGICS INC UNSPON ADS EACH REP 4 ORD SHS Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | |||||
| Cash flow from continuing operating activities | |||||
| Net income from continuing operations | 47.27%-1.14B | 17.84%-2.17B | -207.64%-2.64B | 50.07%-858.71M | ---1.72B |
| Other non cash items | -402.93%-311.41M | -24.97%-61.92M | -827.33%-49.55M | 81.03%-5.34M | ---28.16M |
| Change In working capital | 30.16%403.39M | 436.92%309.91M | 72.47%-91.98M | -136.48%-334.06M | ---141.26M |
| -Change in receivables | -209.54%-430.62M | 179.74%393.14M | -118.79%-493.03M | 7.09%-225.34M | ---242.53M |
| -Change in inventory | 440.59%358.95M | 83.62%-105.39M | -106.56%-643.28M | -6.48%-311.43M | ---292.48M |
| -Change in prepaid assets | -2.45%-108.99M | -175.57%-106.38M | -141.07%-38.6M | 291.32%94M | ---49.13M |
| -Change in other current assets | -167.61%-138.63M | 94.48%205.04M | 91.27%105.43M | -55.25%55.12M | --123.17M |
| Cash from discontinued investing activities | |||||
| Operating cash flow | 107.70%147.81M | 5.24%-1.92B | -558.08%-2.02B | 81.51%-307.69M | ---1.66B |
| Investing cash flow | |||||
| Cash flow from continuing investing activities | |||||
| Net PPE purchase and sale | -21.02%-1.1B | 14.32%-912.94M | -44.16%-1.07B | -102.01%-739.12M | ---365.87M |
| Net intangibles purchase and sale | 44.01%-262.35M | 40.07%-468.6M | -2,296.57%-781.88M | ---32.63M | --0 |
| Net investment purchase and sale | 44.37%-170.15M | -41.33%-305.86M | 95.17%-216.41M | -97.66%-4.48B | ---2.27B |
| Net other investing changes | 60.30%232.36M | 118.44%144.96M | -1,476.84%-785.96M | -876.57%-49.84M | ---5.1M |
| Cash from discontinued investing activities | |||||
| Investing cash flow | 30.42%-998.66M | 46.81%-1.44B | 47.96%-2.7B | -101.80%-5.18B | ---2.57B |
| Financing cash flow | |||||
| Cash flow from continuing financing activities | |||||
| Net issuance payments of debt | -41.48%418.5M | -40.80%715.17M | 240.13%1.21B | 976.30%355.18M | --33M |
| Net common stock issuance | 5.82%2.26B | -46.06%2.13B | -15.27%3.95B | 114.38%4.66B | --2.17B |
| Net other financing activities | -49.07%90.89M | 8,823.65%178.47M | --2M | ---- | ---- |
| Cash from discontinued financing activities | |||||
| Financing cash flow | -10.54%2.59B | -42.20%2.89B | 1.86%5B | 132.88%4.91B | --2.11B |
| Net cash flow | |||||
| Beginning cash position | -25.25%1.02B | 6.52%1.36B | -47.39%1.28B | -46.39%2.43B | --4.52B |
| Current changes in cash | 475.92%1.74B | -264.75%-461.91M | 148.33%280.37M | 72.69%-580.16M | ---2.12B |
| Effect of exchange rate changes | -105.80%-6.88M | 160.19%118.66M | 65.38%-197.14M | -2,353.82%-569.47M | --25.27M |
| End cash Position | 170.20%2.75B | -25.25%1.02B | 6.52%1.36B | -47.39%1.28B | --2.43B |
| Free cash flow | 62.56%-1.24B | 14.77%-3.3B | -258.73%-3.87B | 46.83%-1.08B | ---2.03B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data